Loading clinical trials...
Loading clinical trials...
P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo
Conditions
Interventions
odetiglucan
CDX-1140
Locations
4
United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Start Date
December 15, 2022
Primary Completion Date
March 4, 2024
Completion Date
March 4, 2024
Last Updated
April 10, 2024
NCT07409272
NCT06998940
NCT06381154
NCT07226856
NCT07344220
NCT01660971
Lead Sponsor
HiberCell, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions